Skip to main content
    T

    Tarsus Pharmaceuticals Inc (TARS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $78.68
    -1.60 (-1.99%)

    Market Cap: $3.96B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Tarsus Pharmaceuticals Inc (TARS) Earnings: Report Dates and Results

    Updated Nov 3, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Tarsus Pharmaceuticals (TARS) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Tarsus Pharmaceuticals reported EPS of -$0.78, above the -$1.43 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    65%(17/26)
    Avg Surprise
    +26.64%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.20
    Range-$0.58 - $0.15
    12 analysts
    Revenue Consensus
    $213.66M
    Range$187.78M - $224.70M
    11 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.52
    Range-$0.65 - -$0.32
    3 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.12-533.6%
    60d ago$0.08-793.7%
    30d ago-$0.69+24.6%
    7d ago-$0.60+12.6%
    Current-$0.52
    Revenue Consensus
    $201.71M
    Range$190.00M - $205.78M
    4 analysts

    Next Report

    TARS has an expected report date of Feb 22, 2027.

    TARS Earnings Call

    The latest TARS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 26 quarters below that had an estimate, TARS beat 17, missed 8 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $194.57M, up 63.9% from $118.70M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.78-$1.43N/A+45.45%BeatN/A30 up, 0 downNov 3, 2026$194.57M
    Jun 30, 2026-$0.43-$0.21-$0.28 - -$0.07-104.76%MissN/A53 up, 1 downAug 6, 2026$173.91M
    Mar 31, 2026-$0.16-$0.42-$0.57 - -$0.10+61.90%BeatN/A61 up, 2 downMay 6, 2026$162.05M
    Dec 31, 2025-$0.20-$0.08-$0.09 - $0.07-139.23%MissN/A61 up, 0 downFeb 23, 2026$151.67M
    Sep 30, 2025-$0.30-$0.33-$0.39 - -$0.28+9.09%BeatN/A40 up, 1 downNov 4, 2025$118.70M
    Jun 30, 2025-$0.48-$0.36-$0.48 - -$0.18-33.33%MissN/A30 up, 1 downAug 6, 2025$102.66M
    Mar 31, 2025-$0.64-$0.63-$0.65 - -$0.61-1.59%MissN/A20 up, 1 downMay 1, 2025$78.33M
    Dec 31, 2024-$0.60-$0.82-$1.04 - -$0.48+26.44%BeatN/A30 up, 0 downFeb 25, 2025$66.41M
    Sep 30, 2024-$0.61-$1.00-$1.10 - -$0.82+39.00%BeatN/A81 up, 0 downNov 13, 2024$48.12M
    Jun 30, 2024-$0.83-$0.80-$1.10 - -$0.57-3.75%MissN/A92 up, 0 downAug 8, 2024$40.81M
    Mar 31, 2024-$0.99-$1.25-$1.32 - -$0.89+20.80%BeatN/A82 up, 0 downMay 8, 2024$27.61M
    Dec 31, 2023-$1.31-$1.36-$1.72 - -$1.08+3.68%BeatN/A91 up, 0 downFeb 27, 2024$13.08M
    Sep 30, 2023-$1.27-$1.27-$1.78 - -$1.190.00%In lineN/A60 up, 1 downNov 9, 2023$1.87M
    Jun 30, 2023-$1.17-$1.02-$1.23 - -$0.98-14.71%MissN/A60 up, 0 downAug 10, 2023N/A
    Mar 31, 2023-$0.87-$0.91-$1.16 - -$0.82+4.40%BeatN/A41 up, 0 downMay 9, 2023$2.50M
    Dec 31, 2022-$0.49-$0.69-$0.74 - -$0.61+28.99%BeatN/A40 up, 0 downMar 13, 2023$10.00M
    Sep 30, 2022-$0.84-$1.07-$1.68 - -$0.67+21.50%BeatN/A60 up, 0 downNov 9, 2022N/A
    Jun 30, 2022-$0.22-$0.50N/A+56.00%Beat-166.7%N/A0 up, 0 downAug 11, 2022$15.28M
    Mar 31, 2022-$0.96-$1.06-$1.45 - -$0.16+9.43%Beat-304.3%60 up, 1 downMay 10, 2022$539000
    Dec 31, 2021-$0.72-$0.73-$0.85 - -$0.57+1.37%BeatN/A50 up, 0 downMar 14, 2022$338000
    Sep 30, 2021-$0.76-$0.47-$0.71 - $0.04-61.70%MissN/A3N/ANov 9, 2021$1.24M
    Jun 30, 2021$0.33-$0.33-$0.76 - -$0.16+200.00%BeatN/A3N/AAug 4, 2021$22.02M
    Mar 31, 2021$0.47-$0.13N/A+461.54%BeatN/A2N/AMay 11, 2021$33.43M
    Dec 31, 2020-$0.68-$0.66-$0.69 - -$0.60-3.03%MissN/A4N/AMar 31, 2021N/A
    Sep 30, 2020-$0.50-$0.54-$0.58 - -$0.50+7.41%BeatN/A3N/AOct 16, 2020N/A
    Jun 30, 2020-$0.19-$0.46N/A+57.63%BeatN/AN/AN/ASep 2, 2020N/A
    Last 26 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.62, after -$3.03 the year before. It was -$1.37 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.62N/A
    Dec 31, 2024-$3.03N/A
    Dec 31, 2023-$4.62N/A
    Dec 31, 2022-$2.51N/A
    Dec 31, 2021-$0.68N/A
    Dec 31, 2020-$1.37N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,600 words across 17 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,63617
    2026Q2Jun 30, 20265,92415
    2026Q1Mar 31, 20266,06713
    2025Q4Dec 31, 20256,11914
    2025Q3Sep 30, 20255,56013
    2025Q2Jun 30, 20255,53212
    2025Q1Mar 31, 20255,60311
    2024Q4Dec 31, 20247,86814

    2026Q3 Earnings Call

    Opening remarks

    David Nakasone Head of Investor Relations Thank you. Before we begin, I encourage everyone to visit the Investors section of the Tarsus website to view the press release issued today and related materials we will be discussing today. Joining me on the call today are Bobby Azamian, Chief Executive Officer and Chairman; Neera Clase, our Chief Commercial Officer; Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer; and joining us for Q&A is Dr. Liz Yeu, our Chief Medical Officer, and Sesha Neervannan, our Chief Operating Officer. I'd like to draw your attention to Slide 3, which contains our forward-looking statements. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional details. With that, I will turn the call over to Bobby.

    Bobak Azamian CEO and Chairman Good afternoon, and thank you for joining us. 1 million, $1 billion, 5 and 5. More than 1 million bottles of XDEMVY dispensed, more than $1 billion in cumulative net product sales, and a pipeline with the potential to bring 5 new medicines to patients in the next 5 years. As we celebrate our 10th anniversary, those numbers say a lot about how far Tarsus has come. But what excites me the most is what they tell us about where we can go. We started with a conviction that there were important diseases in eye care hiding in plain sight and that following the science to their root cause could lead to entirely new categories of medicine. XDEMVY showed what that conviction could accomplish. This quarter, we delivered record sales and are again raising our full-year outlook. Neera and Jeff will take you through the details and why we believe XDEMVY is just getting started. I want to talk about our broader ambition: building the next leader in eye care, not one defined by a single drug, but by a repeatable ability to spot a disease the field has overlooked, bring forward a medicine that could change how it's treated, and bring it to patients. That's the standard we're applying across our pipeline. We want to be first or best, and we're treating opportunities where we believe we can make a meaningful difference. With Stargardt disease, that means the potential to help children and young adults preserve vision they would otherwise lose. With IRX-101, it means improving antiseptic preparation for patients receiving repeated retinal injections. And with our existing investigational programs for ocular rosacea and Lyme disease prevention, we have opportunities to address other diseases where patients still need better answers.

    Frequently Asked Questions About TARS

    When is Tarsus Pharmaceuticals's next earnings date?

    Tarsus Pharmaceuticals's next earnings report is expected for Feb 22, 2027.

    Did TARS beat earnings estimates last quarter?

    Yes. Tarsus Pharmaceuticals reported EPS of -$0.78 for the quarter ended Sep 30, 2026, above the -$1.43 estimate, a 45.45% surprise.

    What EPS do analysts expect from TARS next quarter?

    The consensus EPS estimate for Tarsus Pharmaceuticals for the quarter ending Dec 31, 2026 is -$0.20 from 12 analysts, with estimates from -$0.58 to $0.15.

    How often does TARS beat earnings estimates?

    Tarsus Pharmaceuticals beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -17.00%.